创新治疗药物开发商Jazz Pharmaceuticals完成对Chimerix的收购-动脉网

Jazz Pharmaceuticals Completes Acquisition of Chimerix

CISION 等信源发布 2025-04-22 04:05



可切换为仅中文







- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need -

- 添加dordaviprone加强了Jazz的晚期肿瘤学研发管线，并重申了其致力于解决具有显著未满足需求的罕见疾病的承诺 -

DUBLIN

都柏林

，

April 21, 2025

2025年4月21日

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:

/PRNewswire/ -- Jazz Pharmaceuticals plc (纳斯达克:

JAZZ

爵士乐

) ('Jazz' or the 'Company') today announced the successful completion of its acquisition of Chimerix, Inc. ('Chimerix') for approximately

）（“Jazz”或“公司”）今天宣布成功完成了对Chimerix, Inc.（“Chimerix”）的收购，收购金额约为

$935 million

9.35亿美元

in cash. Chimerix is now a wholly owned subsidiary of Jazz.

现金。Chimerix现在是Jazz的全资子公司。

'Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs,' said

“将Chimerix引入Jazz为我们的肿瘤学产品组合增加了一种新颖的药物，并推动了我们解决未满足患者需求的努力，”

Bruce Cozadd

布鲁斯·科扎德

, chairman and chief executive officer of Jazz. 'Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved. We are excited to welcome Chimerix's talented team as we collectively continue to advance dordaviprone, leveraging our development and commercial capabilities to deliver this therapy to patients as soon as the second half of this year.'.

爵士公司的董事长兼首席执行官表示：“Dordaviprone有潜力成为首个也是唯一一个获得FDA批准的针对H3 K27M突变型弥漫性胶质瘤患者的疗法，如果获批，将提供一个前景广阔的近期商业机会。我们很高兴欢迎Chimerix的优秀团队加入，我们将共同努力继续推进Dordaviprone的进展，利用我们的开发和商业化能力，争取在今年下半年尽快将这一疗法带给患者。”

The addition of dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, further diversifies and adds near-term commercial opportunity to Jazz's oncology pipeline. Dordaviprone is currently under Priority Review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for .

Dordaviprone是一种正在开发的针对H3 K27M突变型弥漫性胶质瘤的新型首创小分子治疗药物，它的加入进一步丰富了Jazz的肿瘤学管线，并增加了近期的商业机会。Dordaviprone目前正由美国食品药品监督管理局（FDA）进行优先审查，处方药使用者费用法案（PDUFA）的行动日期已设定为。

August 18, 2025

2025年8月18日

. If approved in the U.S., the therapy may be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Dordaviprone is also being studied in the ongoing Phase 3 ACTION trial to evaluate its use in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending its use into the first-line setting..

如果在美国获得批准，该疗法可能有资格获得罕见儿科疾病优先审查券（PRV）。Dordaviprone也正在正在进行的第3期ACTION试验中进行研究，以评估其在新诊断的、非复发的H3 K27M突变型弥漫性胶质瘤患者接受放射治疗后的使用效果，这可能将其应用扩展到一线治疗。

Transaction Details

交易明细

Jazz's tender offer for all outstanding shares of common stock, par value

爵士乐对所有已发行普通股的要约收购，票面价值

$0.001

0.001美元

per share, of Chimerix expired at one minute after

每股，Chimerix到期时间在一分钟之后

11:59 p.m., Eastern Time

晚上11点59分，东部时间

, on

，打开

April 17, 2025

2025年4月17日

. Jazz has accepted for payment of

. 爵士乐已接受用于支付

$8.55

8.55美元

per share, in cash, without interest and subject to reduction for any applicable withholding taxes, all shares that were validly tendered and not validly withdrawn. Following its acceptance of the tendered shares, Jazz completed the acquisition of Chimerix through the merger of Pinetree Acquisition Sub, Inc., a .

每股现金支付，不计利息，并根据任何适用的预扣税进行扣减，所有有效投标且未有效撤回的股份。在接纳这些投标股份后，Jazz 通过 Pinetree Acquisition Sub, Inc. 的合并完成了对 Chimerix 的收购。

Delaware

特拉华州

corporation, an indirect wholly owned subsidiary of Jazz ('Purchaser') with and into Chimerix (the 'Merger'). As a result of the Merger, the separate existence of Purchaser ceased, and Chimerix continued as the surviving corporation and an indirect wholly owned subsidiary of Jazz. Additional details regarding the tender can be found in a form 8-K filed by Jazz today with the SEC..

公司，Jazz间接全资拥有的子公司（“买方”）与Chimerix合并（“合并”）。作为合并的结果，买方的独立存在终止，Chimerix作为存续公司继续存在，并成为Jazz的间接全资子公司。有关要约收购的更多详细信息，请参见Jazz今天向美国证券交易委员会提交的8-K表格。

About Dordaviprone

关于多拉维普隆

Dordaviprone (ONC201) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). Dordaviprone's unique mechanism of action includes alterations of key epigenetic modifications such as reversal of H3 K27me3-loss, which is the hallmark of H3 K27M-mutant gliomas..

Dordaviprone（ONC201）是一种新型的首创小分子imipridone，可选择性靶向线粒体蛋白酶ClpP和多巴胺受体D2（DRD2）。Dordaviprone的独特作用机制包括改变关键的表观遗传修饰，例如逆转H3 K27me3丢失，这是H3 K27M突变型胶质瘤的标志。

About Jazz Pharmaceuticals

关于Jazz制药公司

Jazz Pharmaceuticals plc (NASDAQ:

爵士制药公司（纳斯达克：

JAZZ

爵士乐

) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments.

）是一家全球生物制药公司，其宗旨是通过创新来改变患者及其家人的生活。我们致力于为患有严重疾病的人群——通常面临有限或无治疗选择——开发改变生活的药物。我们拥有多种已上市的药物组合，包括针对睡眠障碍和癫痫的领先疗法，并且我们的癌症治疗药物组合也在不断扩展。

Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in .

我们以患者为中心、以科学为驱动的方法，推动了我们在肿瘤学和神经科学领域创新治疗的强大研发管道的开创性研究和开发进展。Jazz 总部位于。

Dublin, Ireland

爱尔兰都柏林

with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit

拥有位于多国的研发实验室、制造设施和员工，致力于为全球患者服务。请访问

www.jazzpharmaceuticals.com

for more information.

更多信息，请访问。

Caution Concerning Forward-Looking Statements

关于前瞻性陈述的注意事项

This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Jazz and Chimerix, including statements regarding the prospective benefits of the acquisition, including benefits from dordaviprone's potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and its potential to offer a promising near-term commercial opportunity; the potential for a near-term commercial launch of dordaviprone in the U.S.

本通讯包含涉及未来事件和Jazz及Chimerix未来表现的前瞻性陈述，包括关于收购预期收益的陈述，包括dordaviprone有望成为针对H3 K27M突变型弥漫性胶质瘤患者的首个且唯一的FDA批准疗法及其可能带来的有前景的近期商业机会；dordaviprone在美国短期内上市的潜力。

if approved; the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of dordaviprone in recurrent H3 K27M-mutant diffuse glioma and extend its use in first-line patients; dordaviprone potentially being eligible for a Rare Pediatric Disease PRV; and other statements that are not historical facts.

如果获得批准；正在进行的第三阶段ACTION试验有可能证实dordaviprone在复发性H3 K27M突变型弥漫性胶质瘤中的临床益处，并将其使用范围扩展至一线患者；dordaviprone可能符合罕见儿科疾病优先审评券（PRV）的资格；以及其他非历史事实的声明。

Actual results could differ materially from those anticipated in these forward-looking statements. Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that Jazz and Chimerix will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the effects of the transaction on relationships with employees, customers, suppliers, other business partners or governmental entities; significant transaction costs; unknown or inestimable liabilities; the risk of litigation and/or regulato.

实际结果可能与这些前瞻性陈述中预期的结果有重大差异。可能导致这些前瞻性陈述不准确的风险包括但不限于：关于预测监管批准或行动（如有）的时间或结果的不确定性；与实现收购预期收益能力相关的风险，包括从收购中获得的预期收益无法实现或无法在预期时间内实现的可能性，以及Jazz和Chimerix无法成功整合或整合可能比预期更困难、耗时或成本更高的风险；该交易对员工、客户、供应商、其他商业伙伴或政府实体关系的影响；重大的交易成本；未知或无法估量的负债；诉讼和/或监管风险。

December 31, 2024

2024年12月31日

and future filings and reports. Other risks and uncertainties of which the Company is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this press release are made only as of the date hereof, even if they are subsequently made available by the Company on its website or otherwise.

以及未来的文件和报告。公司目前尚未意识到的其他风险和不确定性也可能影响其前瞻性声明，并可能导致实际结果和事件的时间与预期有重大差异。本新闻稿中所做的前瞻性声明仅截至本日期作出，即使公司随后在其网站或其他途径提供这些声明。

The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made..

公司不承担更新或补充任何前瞻性陈述的义务，以反映实际结果、新信息、未来事件、预期变化或其他在作出前瞻性陈述之日后存在的情况。

Contacts

联系人

Investors:

投资者：

Jeff Macdonald

杰夫·麦克唐纳

Executive Director, Investor Relations

投资者关系执行董事

Jazz Pharmaceuticals plc

爵士制药公司

InvestorInfo@jazzpharma.com